Novel drug regimens, autologous stem cell transplant (ASCT), and modern supportive care are prolonging remission, improving ...

Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.

A comprehensive US analysis showed that progress in multiple myeloma survival has not been shared equally, with significant disparities persisting despite improved therapies.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients are older than 75, and 10% are older than 80. Along with this worldwide ...

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.